Cargando…
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). However, it is still unclear how FXR agonists protect against NASH and which cell type is the main target of FXR agonists....
Autores principales: | Goto, Toshihiro, Itoh, Michiko, Suganami, Takayoshi, Kanai, Sayaka, Shirakawa, Ibuki, Sakai, Takeru, Asakawa, Masahiro, Yoneyama, Toshihiro, Kai, Toshihiro, Ogawa, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970222/ https://www.ncbi.nlm.nih.gov/pubmed/29802399 http://dx.doi.org/10.1038/s41598-018-26383-8 |
Ejemplares similares
-
Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver
por: Itoh, Michiko, et al.
Publicado: (2020) -
Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis
por: Asakawa, Masahiro, et al.
Publicado: (2019) -
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
por: Kawakubo, Mitsuhiro, et al.
Publicado: (2020) -
Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice
por: Konuma, Kuniha, et al.
Publicado: (2015) -
Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)